Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).
Schulte C, Gauler T, Pöttgen C, Friedel G, Kopp HG, Fischer B, Schmidberger H, Kimmich M, Budach W, Cordes S, Wienker J, Metzenmacher M, de Los Rios RH, Spengler W, De Ruysscher D, Belka C, Welter S, Luetke-Brintrup D, Guberina M, Oezkan F, Darwiche K, Schuler M, Jöckel KH, Aigner C, Stamatis G, Stuschke M, Eberhardt WEE. Schulte C, et al. Among authors: de ruysscher d. Int J Cancer. 2025 Jan 1;156(1):154-163. doi: 10.1002/ijc.35131. Epub 2024 Aug 28. Int J Cancer. 2025. PMID: 39198970 Clinical Trial.
Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study.
Wanders R, Steevens J, Botterweck A, Dingemans AM, Reymen B, Baardwijk Av, Borger J, Bootsma G, Pitz C, Lunde R, Geraedts W, Lambin P, De Ruysscher D. Wanders R, et al. Among authors: de ruysscher d. Eur J Cancer. 2011 Dec;47(18):2691-7. doi: 10.1016/j.ejca.2011.06.023. Epub 2011 Jul 4. Eur J Cancer. 2011. PMID: 21733675 Free article.
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P. De Ruysscher D, et al. J Thorac Oncol. 2012 Oct;7(10):1547-55. doi: 10.1097/JTO.0b013e318262caf6. J Thorac Oncol. 2012. PMID: 22982655 Free article. Clinical Trial.
Strategies for improving outcomes in NSCLC: a look to the future.
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Stahel R, et al. Among authors: de ruysscher d. Lung Cancer. 2013 Dec;82(3):375-82. doi: 10.1016/j.lungcan.2013.08.025. Epub 2013 Sep 8. Lung Cancer. 2013. PMID: 24094287 Free article. Review.
A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Dingemans AM, Bootsma G, van Baardwijk A, Reymen B, Wanders R, Brans B, Das M, Hochstenbag M, van Belle A, Houben R, Lambin P, de Ruysscher D. Dingemans AM, et al. Among authors: de ruysscher d. J Thorac Oncol. 2014 May;9(5):710-6. doi: 10.1097/JTO.0000000000000151. J Thorac Oncol. 2014. PMID: 24722157 Free PMC article. Clinical Trial.
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M. Eberhardt WE, et al. Among authors: de ruysscher d. J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2. J Clin Oncol. 2015. PMID: 26527789 Clinical Trial.
ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer.
Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePéchoux C, Van Houtte P. Nestle U, et al. Among authors: de ruysscher d. Radiother Oncol. 2018 Apr;127(1):1-5. doi: 10.1016/j.radonc.2018.02.023. Epub 2018 Mar 28. Radiother Oncol. 2018. PMID: 29605476
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Peters S, et al. Among authors: de ruysscher d. Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31200833 Clinical Trial.
Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement.
Guckenberger M, Belka C, Bezjak A, Bradley J, Daly ME, DeRuysscher D, Dziadziuszko R, Faivre-Finn C, Flentje M, Gore E, Higgins KA, Iyengar P, Kavanagh BD, Kumar S, Le Pechoux C, Lievens Y, Lindberg K, McDonald F, Ramella S, Rengan R, Ricardi U, Rimner A, Rodrigues GB, Schild SE, Senan S, Simone CB 2nd, Slotman BJ, Stuschke M, Videtic G, Widder J, Yom SS, Palma D. Guckenberger M, et al. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):631-640. doi: 10.1016/j.ijrobp.2020.05.012. Int J Radiat Oncol Biol Phys. 2020. PMID: 32589990 Free PMC article.
506 results